Ionis Pharmaceuticals (IONS) Tops Q4 EPS by 76c, provides guidance

Ionis Pharmaceuticals (NASDAQ: IONS) reported Q4 EPS of ($0.06), $0.76 better than the analyst estimate of ($0.82). Revenue for the quarter came in at $325 million versus the consensus estimate of $174.13 million.

GUIDANCE:

Ionis Pharmaceuticals sees Q1 2024 revenue of $575 million, versus the consensus of $635.3 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Citi sees this stock as primary lithium demand beneficiary, upgrades to Buy
• Berenberg Downgrades Umicore SA (UMI:BB) (UMICY) to Hold